You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 276 No. 8, August 28, 1996 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Clinical Investigation
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Synthetic Human Parathyroid Hormone 1-34 vs Calcitriol and Calcium in the Treatment of Hypoparathyroidism

Results of a Short-term Randomized Crossover Trial

Karen K. Winer, MD; Jack A. Yanovski, MD, PhD; Gordon B. Cutler, Jr, MD

JAMA. 1996;276(8):631-636.


Abstract

Objective.
—To test the hypothesis that treatment with human parathyroid hormone 1-34 (PTH 1-34) can maintain normal serum calcium without hypercalciuria in patients with hypoparathyroidism.

Design.
—Randomized crossover trial lasting 20 weeks. Each 10-week arm consisted of a 2-week inpatient dose-adjustment phase followed by an 8-week outpatient phase.

Setting.
—Tertiary care center.

Patients.
—A total of 10 patients with hypoparathyroidism were enrolled consecutively over a 15-month period. Half of the patients were prior National Institutes of Health patients, and the other 5 patients were referred from outside physicians.

Interventions.
—A dose of PTH 1-34 was administered each morning by subcutaneous injection. Calcitriol was given orally twice daily with supplemental calcium carbonate.

Main Outcome Measures.
—Serum and urine calcium and phosphorus levels.

Results.
—Once-daily treatment with PTH 1-34 maintained serum calcium in the normal range with decreased urine calcium excretion (P<.05 at 2 weeks and P<.01 at 10 weeks) compared with calcitriol treatment. Biochemical markers of bone turnover increased significantly (P<.01 at 10 weeks) during PTH 1-34 treatment.

Conclusions.
—Treatment of hypoparathyroidism with PTH 1-34 reduces urine calcium excretion compared with treatment with calcitriol and calcium.



Author Affiliations

From the Developmental Endocrinology Branch of the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Md.


Footnotes

Reprints: Karen K. Winer, MD, NICHD/DEB/SDE, Bldg 10, Room 10N262, 10 Center Dr, MSC 1862, National Institutes of Health, Bethesda, MD 20892-1862.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide
Puig-Domingo et al.
Eur J Endocrinol 2008;159:653-657.
ABSTRACT | FULL TEXT  

Hypoparathyroidism: Is It Time for Replacement Therapy?
Horwitz and Stewart
J. Clin. Endocrinol. Metab. 2008;93:3307-3309.
FULL TEXT  

Effects of Once Versus Twice-Daily Parathyroid Hormone 1-34 Therapy in Children with Hypoparathyroidism
Winer et al.
J. Clin. Endocrinol. Metab. 2008;93:3389-3395.
ABSTRACT | FULL TEXT  

Hypoparathyroidism
Shoback
NEJM 2008;359:391-403.
FULL TEXT  

A Hypocalcemic Child with a Novel Activating Mutation of the Calcium-Sensing Receptor Gene: Successful Treatment with Recombinant Human Parathyroid Hormone
Mittelman et al.
J. Clin. Endocrinol. Metab. 2006;91:2474-2479.
ABSTRACT | FULL TEXT  

Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1-34) Versus Calcitriol and Calcium
Winer et al.
J. Clin. Endocrinol. Metab. 2003;88:4214-4220.
ABSTRACT | FULL TEXT  

Hyperparathyroid and Hypoparathyroid Disorders
Marx
NEJM 2000;343:1863-1875.
FULL TEXT  

Comparison of Hypocalcemic Hypercalciuria between Patients with Idiopathic Hypoparathyroidism and Those with Gain-of-Function Mutations in the Calcium-Sensing Receptor: Is It Possible to Differentiate the Two Disorders?
Yamamoto et al.
J. Clin. Endocrinol. Metab. 2000;85:4583-4591.
ABSTRACT | FULL TEXT  

A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1-34 in Treatment of Hypoparathyroidism
Winer et al.
J. Clin. Endocrinol. Metab. 1998;83:3480-3486.
ABSTRACT | FULL TEXT  

Sporadic Hypoparathyroidism Caused by de Novo Gain- of-Function Mutations of the Ca2+-Sensing Receptor
De Luca et al.
J. Clin. Endocrinol. Metab. 1997;82:2710-2715.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.